Monoclonal Antibody Therapy for Hairy Cell Leukemia

Hematology/Oncology Clinics of North America

Volumn 20, Issue 5, 2006, Pages 1125-1136

  Thomas, Deborah A ^a   Ravandi, Farhad ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASILIXIMAB; BL 22; CD20 ANTIBODY; CD22 ANTIBODY; CD22 ANTIBODY PSEUDOMONAS EXOTOXIN CONJUGATE; CLADRIBINE; EPRATUZUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOTOXIN; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; HAIRY CELL LEUKEMIA; HUMAN; LYMPHOCYTOPENIA; META ANALYSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; LEUKEMIA, HAIRY CELL; NEOPLASM, RESIDUAL;

EID: 33748752626     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.06.011     Document Type: Review

References (94)

1. Bouroncle B.A., Wiseman B.K., and Doan C.A. Leukemic reticuloendotheliosis. Blood 13 7 (1958) 609-630
2. Burns G.F., Cawley J.C., Worman C.P., et al. Multiple heavy chain isotypes on the surface of the cells of hairy cell leukemia. Blood 52 6 (1978) 1132-1147
3. Kluin-Nelemans H.C., Krouwels M.M., Jansen J.H., et al. Hairy cell leukemia preferentially expresses the IgG3-subclass. Blood 75 4 (1990) 972-975
4. Forconi F., Sahota S.S., Raspadori D., et al. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood 98 4 (2001) 1174-1181
5. Forconi F., Sahota S.S., Raspadori D., et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood 104 10 (2004) 3312-3317
6. Vanhentenrijk V., Tierens A., Wlodarska I., et al. V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia 18 10 (2004) 1729-1732
7. Basso K., Liso A., Tiacci E., et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 199 1 (2004) 59-68
8. Robbins B.A., Ellison D.J., Spinosa J.C., et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82 4 (1993) 1277-1287
9. Ginaldi L., De Martinis M., Matutes E., et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51 5 (1998) 364-369
10. Quigley M.M., Bethel K.J., Sharpe R.W., et al. CD52 expression in hairy cell leukemia. Am J Hematol 74 4 (2003) 227-230
11. Sausville J.E., Salloum R.G., Sorbara L., et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 119 2 (2003) 213-217
12. Piro L.D., Carrera C.J., Carson D.A., et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322 16 (1990) 1117-1121
13. Estey E.H., Kurzrock R., Kantarjian H.M., et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79 4 (1992) 882-887
14. Piro L.D., Ellison D.J., and Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 14 Suppl 1 (1994) 121-125
15. Tallman M.S., Hakimian D., Rademaker A.W., et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 88 6 (1996) 1954-1959
16. Hoffman M.A., Janson D., Rose E., et al. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 15 3 (1997) 1138-1142
17. Tallman M.S., and Zakarija A. Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease. Transfus Apher Sci 32 1 (2005) 99-103
18. Chadha P., Rademaker A.W., Mendiratta P., et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 106 1 (2005) 241-246
19. Zinzani P.L., Tani M., Marchi E., et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 89 3 (2004) 309-313
20. Jehn U., Bartl R., Dietzfelbinger H., et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18 9 (2004) 1476-1481
21. Goodman G.R., Burian C., Koziol J.A., et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21 5 (2003) 891-896
22. Jansen J., and Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 47 8 (1981) 2066-2076
23. Quesada J.R., Reuben J., Manning J.T., et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310 1 (1984) 15-18
24. Worman C.P., Catovsky D., Bevan P.C., et al. Interferon is effective in hairy-cell leukaemia. Br J Haematol 60 4 (1985) 759-763
25. Ratain M.J., Golomb H.M., Vardiman J.W., et al. Treatment of hairy cell leukemia with recombinant alpha 2 interferon. Blood 65 3 (1985) 644-648
26. Lauria F., Benfenati D., Raspadori D., et al. Retreatment with 2-CdA of progressed HCL patients. Leuk Lymphoma 14 Suppl 1 (1994) 143-145
27. Kreitman R.J., Wilson W.H., Bergeron K., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345 4 (2001) 241-247
28. Kreitman R.J., Squires D.R., Stetler-Stevenson M., et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23 27 (2005) 6719-6729
29. Saven A., Burian C., Koziol J.A., et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92 6 (1998) 1918-1926
30. + lymphocyte counts in patients with hairy cell leukemia. Blood 83 10 (1994) 2906-2911
31. Betticher D.C., Fey M.F., von Rohr A., et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 5 1 (1994) 57-64
32. Cheson B.D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13 9 (1995) 2431-2448
33. Legrand O., Vekhoff A., Marie J.P., et al. Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects. Br J Haematol 99 1 (1997) 165-167
34. Ravandi F., and O'Brien S. Infections associated with purine analogs and monoclonal antibodies. Blood Rev 19 5 (2005) 253-273
35. Albitar M., Do K.A., Johnson M.M., et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 101 5 (2004) 999-1008
36. Lim S.H., Davey G., and Marcus R. Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet 341 8842 (1993) 432-433
37. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 10 (2002) 3554-3561
38. Coleman M., Goldenberg D.M., Siegel A.B., et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 9 10 Pt 2 (2003) 3991S-3994S
39. Anderson K.C., Bates M.P., Slaughenhoupt B.L., et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63 6 (1984) 1424-1433
40. Einfeld D.A., Brown J.P., Valentine M.A., et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7 3 (1988) 711-717
41. Valentine M.A., Meier K.E., Rossie S., et al. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 264 19 (1989) 11282-11287
42. Tedder T.F., Boyd A.W., Freedman A.S., et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135 2 (1985) 973-979
43. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 2 (1994) 435-445
44. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 6 (1997) 2188-2195
45. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 8 (1998) 2825-2833
46. Piro L.D., White C.A., Grillo-Lopez A.J., et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10 6 (1999) 655-661
47. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 8 (2001) 2165-2170
48. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 8 (2001) 2153-2164
49. Manshouri T., Do K.A., Wang X., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101 7 (2003) 2507-2513
50. Hagberg H., and Rituximab L.L. A chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 115 3 (2001) 609-611
51. Lauria F., Lenoci M., Annino L., et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 86 10 (2001) 1046-1050
52. Nieva J., Bethel K., and Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102 3 (2003) 810-813
53. Thomas D.A., O'Brien S., Bueso-Ramos C., et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 102 12 (2003) 3906-3911
54. Zinzani P.L., Ascani S., Piccaluga P.P., et al. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 18 22 (2000) 3875-3877
55. Hoffman M., and Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol 109 4 (2000) 900-901
56. Pollio F., Pocali B., Palmieri S., et al. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. Ann Hematol 81 12 (2002) 736-738
57. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 21 (2003) 3940-3947
58. Farag S.S., Flinn I.W., Modali R., et al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103 4 (2004) 1472-1474
59. Teeling J.L., French R.R., Cragg M.S., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 6 (2004) 1793-1800
60. Stein R., Qu Z., Chen S., et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10 8 (2004) 2868-2878
61. Nagajothi N., Matsui W.H., Mukhina G.L., et al. Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins. Leuk Lymphoma 45 4 (2004) 795-799
62. Filleul B., Delannoy A., Ferrant A., et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8 7 (1994) 1153-1156
63. Wheaton S., Tallman M.S., Hakimian D., et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 87 4 (1996) 1556-1560
64. Matutes E., Meeus P., McLennan K., et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol 98 2 (1997) 375-383
65. Di Gaetano N., Xiao Y., Erba E., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114 4 (2001) 800-809
66. Cervetti G., Galimberti S., Andreazzoli F., et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 73 6 (2004) 412-417
67. Ravandi F., Jorgensen J.L., O'Brien S.M., et al. Eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL). Blood 107 12 (2006) 4658-4662
68. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 18 (2005) 4079-4088
69. Byrd J.C., Rai K., Peterson B.L., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105 1 (2005) 49-53
70. Ginaldi L., De Martinis M., Matutes E., et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22 2 (1998) 185-191
71. Faderl S., Coutre S., Byrd J.C., et al. The evolving role of alemtuzumab in management of patients with CLL. Leukemia 19 12 (2005) 2147-2152
72. Hale G., Swirsky D., Waldmann H., et al. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol 60 1 (1985) 41-48
73. Hale G., Xia M.Q., Tighe H.P., et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 35 3 (1990) 118-127
74. Dyer M.J. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26 (1999) (5) (Suppl 14):52-7
75. Belov L., de la Vega O., dos Remedios C.G., et al. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res 61 11 (2001) 4483-4489
76. Fietz T., Rieger K., Schmittel A., et al. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J 5 5 (2004) 451-452
77. Cordone I., Annino L., Masi S., et al. Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia. J Clin Pathol 48 10 (1995) 955-960
78. Engel P., Nojima Y., Rothstein D., et al. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol 150 11 (1993) 4719-4732
79. Engel P. CD22. J Biol Regul Homeost Agents 14 4 (2000) 295-298
80. Siegel A.B., Goldenberg D.M., Cesano A., et al. CD22-directed monoclonal antibody therapy for lymphoma. Semin Oncol 30 4 (2003) 457-464
81. Carnahan J., Wang P., Kendall R., et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 9 10 Pt 2 (2003) 3982S-3990S
82. Shih L.B., Lu H.H., Xuan H., et al. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56 4 (1994) 538-545
83. Leonard J.P., Coleman M., Ketas J.C., et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21 16 (2003) 3051-3059
84. Leonard J.P., Coleman M., Ketas J.C., et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 10 16 (2004) 5327-5334
85. Faderl S., Thomas D.A., O'Brien S., et al. Experience with alemtuzumab plus rituximab in 2 patients with relapsed and refractory lymphoid malignancies. Blood 101 9 (2003) 3413-3415
86. Leonard J.P., Coleman M., Ketas J., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23 22 (2005) 5044-5051
87. Venugopal P., Sivaraman S., Huang X.K., et al. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 24 5 (2000) 411-415
88. Stockmeyer B., Elsasser D., Dechant M., et al. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods 248 1-2 (2001) 103-111
89. Hernandez-Ilizaliturri F.J., Jupudy V., Reising S., et al. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 46 12 (2005) 1775-1784
90. Ferrajoli A., O'Brien S.M., Faderl S.H., et al. Rituximab plus GM-CSF for patients with chronic lymphocytic leukemia. Blood 106 Suppl 1 (2005) 214a
91. Rossi J.F., Lu Z.Y., Quittet P., et al. Rituximab activity is potentiated by GM-CSF in patients with relapsed, follicular lymphoma: results of a phase II study. Blood 106 Suppl 1 (2005) 684a
92. Davis R.S., Wang Y.H., Kubagawa H., et al. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U S A 98 17 (2001) 9772-9777
93. Davis R.S., Dennis Jr. G., Kubagawa H., et al. Fc receptor homologs (FcRH1-5) extend the Fc receptor family. Curr Top Microbiol Immunol 266 (2002) 85-112
94. Ise T., Maeda H., Santora K., et al. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res 11 1 (2005) 87-96